Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent $O^6$-methylguanine-DNA methyltransferase

Yuanyuan Gao,1 Abbas Fotovati,1 Cathy Lee,1 Michelle Wang,1 Gilbert Cote,3 Emma Guns,4 Brian Toyota,2 Damien Faury,5 Nada Jabado,5 Michelle Wang,1 Gilbert Cote,3 Emma Guns,4 Brian Toyota,2 Damien Faury,5 Nada Jabado,5 and Sandra E. Dunn1

1Departments of Pediatrics, Experimental Medicine and Medical Genetics, Child and Family Research Institute, University of British Columbia; 2Department of Surgery, Prostate Cancer Research, Jack Bell Research Laboratories; 3Division of Neurosurgery, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; 4Division of Internal Medicine, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; and 5Montreal Children’s Hospital, Division of Hematology and Oncology, McGill University, Montreal, Quebec, Canada

Abstract
Glioblastoma multiforme (GBM) is an aggressive type of brain tumor where <3% of newly diagnosed cases in the patients will survive >5 years. In adults, GBM is the most common type of brain tumor. It is rarer in children, where it constitutes ~15% of all brain tumors diagnosed. These tumors are often invasive, making surgical resection difficult. Further, they can be refractory to current therapies such as temozolomide. The current dogma is that temozolomide resistance rests on the expression of $O^6$-methylguanine-DNA methyltransferase (MGMT) because it cleaves methylated DNA adducts formed by the drug. Our laboratory recently reported that another drug resistance gene known as the Y-box binding protein-1 (YB-1) is highly expressed in primary GBM but not in normal brain tissues based on the evaluation of primary tumors. We therefore questioned whether GBM depend on YB-1 for growth and/or response to temozolomide. Herein, we report that YB-1 inhibition reduced tumor cell invasion and growth in monolayer as well as in soft agar. Moreover, blocking this protein ultimately delayed tumor onset in mice. Importantly, inhibiting YB-1 enhanced temozolomide sensitivity in a manner that was independent of MGMT in models of adult and pediatric GBM. In conclusion, inhibiting YB-1 may be a novel way to improve the treatment of GBM. [Mol Cancer Ther 2009;8(12):3276–84]

Introduction
Glioblastoma multiformes (GBM) are WHO grade 4 astrocytomas that are very aggressive types of brain tumors associated with poor prognosis despite recent therapeutic advancement. This is the case for patients diagnosed with GBM whether they are children or adults. Pediatric GBM (pediatric grade 4 astrocytoma) are rare and deadly brain tumors that account for 8% to 12% of all pediatric brain tumors and are the third leading cause of death in children ages <16 years (1). The 3-year survival of pediatric GBM patients is <20% (2). Current treatment for pediatric GBM is surgical resection followed by radiation therapy and chemotherapy. The most potent antitumor agent against adult and pediatric glioblastomas thus far is temozolomide, an orally administered DNA-methylating agent. Patients receiving temozolomide treatment show enhanced response rates; for example, those on temozolomide treatment have a 10- to 12-month survival rate compared with 4 months without such treatment (3). Temozolomide in combination with radiation also increases survival, but again this is only by a few months rather than years (4). Perhaps there is the potential to enhance the therapeutic benefits of temozolomide by a combinatorial drug regimen including molecular targeted therapy to ultimately improve cure rates.

We recently reported that the Y-box binding protein-1 (YB-1), an oncogenic transcription/translation factor, is highly expressed in primary pediatric glioblastoma (2), yet its functional role in these tumors has not been described. YB-1 controls the oncogene by shuttling between cytoplasm and nucleus. In the cytoplasm, YB-1 functions as a translation factor. On phosphorylation by AKT (5) or RSK (6) at Ser$^{102}$ located in the DNA/RNA-binding domain, YB-1 translocates into nucleus where it regulates transcription (5) by binding to Y-box (sequence motif CTGATTGG) in the promoter regions of growth-promoting genes such as Her-2 and EGFR (7). YB-1 has also been implicated in...
drug resistance by increasing the expression of multidrug resistance gene (mdr1), multidrug resistance–related protein-1 (mrp1), and major vault protein (mvp; ref. 8). Much of what is known about YB-1 was revealed through studies of adult cancers; however, very little is known about the functional role of YB-1 in pediatric malignancies. It has recently been shown that the expression of nuclear YB-1 in glioma models can be used to increase cell killing when cells are exposed to cytotoxic viruses in combination with the chemotherapeutic agent irinotecan or radiation (9, 10). This is because YB-1 facilitates viral replication and therefore can be used for gene therapy approaches. YB-1, also called nucleas-sensitive element binding protein 1 (NSEP1), is among the top genes that are differentially expressed in pediatric glioblastoma, as well as in adult glioblastoma, when compared with control brain tissues (11, 12). YB-1 is detectable in 100% (14 of 14 cases) of primary pediatric glioblastoma tumor tissues based on quantitative reverse transcription-PCR, whereas at the protein level it is detectable in 81% (26 of 32 cases) of tumors at high levels (2, 11). Thus, YB-1 is a fairly common molecular marker in both primary pediatric GBM and adult GBM.

We sought to characterize the role of YB-1 in mediating GBM growth, invasion, and tumorigenesis. Furthermore, we investigated the possibility that inhibiting YB-1 may sensitize pediatric GBM and/or adult GBM to temozolomide.

**Material and Methods**

**Cell Culture**

The SF188 and SJG2 pediatric glioblastoma cell lines as well as U251 adult glioblastoma cells were obtained from Dr. Nada Jabado (University of McGill). T98G cells (adult glioblastoma) were purchased from the American Tissue Culture Collection. The cell lines were cultured in MEM/Earle’s BSS (Hyclone) and DMEM/high glucose (Hyclone), respectively, supplemented with 10% fetal bovine serum, as chemoattractants. Cells were transfected with either 10 μg shYB-1 or the empty vector and selected in G418 until stable pooled clones were established. This method was used to establish stable shYB-1–expressing cell lines from the SF188 and U251 parental cells. Loss of YB-1 expression was confirmed to be >90% by immunoblotting and quantitative reverse transcription-PCR. For the transient inhibition of YB-1, small interfering RNA (siRNA) was used. In this case, 10 nmol/L control (oligonucleotide sequence UUCGCCAACGUGUCACGU; Qiagen) or YB-1 siRNA (oligonucleotide sequence CCACGCAAUAC-CAGCAAA; Dharmaco) was introduced into the SF188 cells using RNAIMAX (Invitrogen). Following transient transfection, levels of YB-1 were evaluated by immunoblotting and tumor cell growth was assessed after 8 days using MTS assay (Promega) for SF188 cells. Similarly, T98G cells were treated with YB-1 siRNA (5 nmol/L) as described above and tumor cell growth was assessed 1, 2, and 3 days after transfection using MTS assay (Promega).

**Immunoblotting**

Harvested cells were washed with cold PBS and pelleted by centrifugation at 3,000 rpm for 3 min. After the supernatant was aspirated, the pellets were resuspended in 5× sample loading buffer, boiled for 5 min, and detected by immunoblotting using the following antibodies: anti–YB-1 (1:1,500; Abcam), anti–phosphorylated histone 2AX (pH2AXS139; 1:1,000; Abcam), anti–O6-methylguanine-DNA methyltransferase (MGMT; 1:200; Abcam), anti–pYB-1S102 (1:1,000; Cell Signaling Technology), and anti–vinculin (1:1,000; Sigma).

** Invasion Assay**

Cellular invasion was evaluated by quantifying the number of cells that migrated through a polyethylene terephthalate membrane coated with a layer of Matrigel (13). Briefly, tumor cells (1 × 10^5) in 100 μL warmed 0.1% fetal bovine serum MEM/Earle’s BSS) were seeded on the top of Transwell inserts containing 40 μL diluted Matrigel (Matrigel/serum-free medium = 1:8). The bottom chamber was filled with 600 μL MEM/Earle’s BSS, supplemented with 10% fetal bovine serum, as chemoattractants. Cells were cultured for 16 to 27 h at 37°C in a 5% CO2 incubator. The cells that did not invade were subsequently scraped off the top chamber and the membranes were fixed with 500 μL ice-cold methanol (100%) for 5 min at room temperature. Cells were visualized by staining with Hoechst (0.5 μg/mL in PBS) for 5 min. Following 3 × 5 min PBS washes, membranes were placed on the glass slides with gelvatol on the surface. The cells that had migrated through the membranes were quantified in three randomly chosen visual fields under the microscope.

**Soft-Agar Assays**

MEM/Earle’s BSS medium (2×; Hyclone) was mixed with 1.2% agarose solution in 1:1 ratio. The mixture was placed on the glass slides with gelvatol on the surface. The cells that had migrated through the membranes were quantified in three randomly chosen visual fields under the microscope.

**Short Hairpin RNA and Small Interfering RNA Transfections to Silence YB-1**

SF188 wild-type cells were plated in 6-well culture plates (3 × 10^5 per well) 24 h before transfection. Cells were transfected with either 10 μg shYB-1 or the empty vector and selected in G418 until stable pooled clones were established. This method was used to establish stable shYB-1–expressing cell lines from the SF188 and U251 parental cells. Loss of YB-1 expression was confirmed to be >90% by immunoblotting and quantitative reverse transcription-PCR. For the transient inhibition of YB-1, small interfering RNA (siRNA) was used. In this case, 10 nmol/L control (oligonucleotide sequence UUCGCCAACGUGUCACGU; Qiagen) or YB-1 siRNA (oligonucleotide sequence CCACGCAAUAC-CAGCAAA; Dharmaco) was introduced into the SF188 cells using RNAIMAX (Invitrogen). Following transient transfection, levels of YB-1 were evaluated by immunoblotting and tumor cell growth was assessed after 8 days using MTS assay (Promega) for SF188 cells. Similarly, T98G cells were treated with YB-1 siRNA (5 nmol/L) as described above and tumor cell growth was assessed 1, 2, and 3 days after transfection using MTS assay (Promega).
was added into 6-well plates with 1 mL in each well to create the bottom layer. The top layer was made by adding SF188 cells (5 × 10^4 per well) into a 1:1 mixture of 2× medium and a 0.6% agarose solution. For drug treatment study, the cell layer was composed of tumor cells, 1:1 mixture of 2× medium and 1.2% agarose, and varying concentrations of temozolomide (British Columbia Cancer Agency). The assays were incubated at 37°C in a 5% CO₂ incubator for 28 days. The size and number of colonies were measured under a microscope (Leica DMIL). The experiment was done in triplicate on three different occasions.

**Effect of Silencing YB-1 in Xenograft Model**

SF188 cells have been shown to be tumorigenic in rats (14); however, it has not been tested in mice. We conducted a pilot study to determine the conditions required for tumor formation in mice. The SF188 control cells were injected s.c. into the lower hind flank of female 6- to 8-week-old BALB/c nu/nu mice (n = 12). The weight of the mice and the size of the tumors were measured for 30 days and the tumors were harvested at the end of the study. Following this pilot study, SF188 control and shYB-1 cells were injected bilaterally into the lower hind flank of female nu/nu mice (left, SF188 control; right, SF188 shYB-1; n = 8). The weight of the mice and the size of the tumors on each side were measured using calipers for 28 days. In detail, cells were washed with HBSS (Invitrogen) twice and counted to prepare 1 × 10⁶ cells, which were subsequently mixed with Matrigel (BD Bioscience) in a 1:1 ratio with a total volume of 150 μL. The tumor cells/Matrigel was injected s.c. into the left or right lower hind region of female nu/nu mice using a 26-gauge needle. The weight of the mice and the size of the tumor on each side were measured using calipers for 28 days. Mice were terminated with CO₂. Tumors were frozen in liquid nitrogen at the time of harvest. Tumor volumes were calculated from the equation: (4/3)π(a/2) × (b/2) × (c/2), where

---

**Figure 1.** Cellular invasion through Matrigel was inhibited by transient and stable YB-1 knockdown. **A,** YB-1 and pYB-1<sup>S102</sup> proteins were highly expressed in the nucleus of SF188 wild-type (WT) cells. **B,** levels of YB-1 and pYB-1<sup>S102</sup> were confirmed by immunoblotting. Silencing YB-1 with either shRNA (right) or siRNA (left) decreased its expression by >90%. Vinculin was measured as a loading control. **C,** SF188 control and shYB-1 cells were assessed using the Matrigel invasion assay. **D,** changes in invasion were confirmed using transient inhibition of YB-1 with siRNA. The cells were treated with siYB-1 for 24 h, and on the following day, the cells were placed into the Matrigel invasion assay. The transient loss of YB-1 caused a marked suppression of invasion. Representative images of invasive cells. Lipo, Lipofectamine-treated cells; Ctrl, control siRNA-treated cells.

---

Mol Cancer Ther 2009;8(12). December 2009

Published OnlineFirst December 8, 2009; DOI: 10.1158/1535-7163.MCT-09-0478
a, b, and c were the width, length, and depth of the tumors, respectively. All studies were conducted in accordance with the University of British Columbia Animal Care and Use Guidelines. Differences in tumor size was determined using a Student’s t test where significance was determined if P < 0.05.

Apoptosis Assays

SF188 control and shYB-1 cells were treated with various concentrations of Taxol or temozolomide and incubated for 24 h before being stained with Annexin V (Promega). Staining was done according to the manufacturer’s protocol as described previously by us (15). In brief, the harvested cells were washed once with cold PBS followed by 15-min incubation with 1× binding buffer containing Annexin V and 7AAD. Then, 250 μL of 1× binding buffer were added into each sample and flow cytometry analysis was done within 1 h. The experiment was repeated on three separate occasions. Following this, we confirmed that the cells were undergoing apoptosis by evaluating changes in chromatin condensation. SF188 control and shYB-1 cells (3,000 per well) were seeded in a 96-well plate and treated with temozolomide or Taxol with various concentrations for 24 h. After the medium was aspirated, 100 μL PBS containing 2% paraformaldehyde and Hoechst dye (1 μg/mL) was added to each well and the cells were kept at room temperature for 20 min. The plates were analyzed and the images were taken on the ArrayScan VTI Reader (Cellomics).

Analysis of YB-1 Expression in Adult Glioblastoma

Gene Expression Omnibus6 data were mined to examine YB-1 expression in adult GBM (16). GSE4290 provided the largest data set for a comparison containing 23 samples from epilepsy patients used as nontumor samples and 81 grade 4 adult GBM samples (17). Expression and clustering analyses were done as described previously (12). We used probe sets described previously as segregating nontumor from tumor samples based on known functions in general and alternative splicing, RNA export, RNA degradation, miRNA processing, and nonsense-mediated decay (12). Hierarchical clustering was done with the EBI Profiler tool

Figure 2. Knockdown of YB-1 reduced tumor cell growth and delayed tumor formation. A, cell growth was also assessed in monolayer following YB-1 inhibition using siRNA. The growth of SF188 cells was inhibited by ~70% after 8 d in culture using a MTS assay. Each treatment group was evaluated in replicates of six. B, SF188 control and shYB-1 cells were plated in soft agar for 28 d. Colonies ≥70 μm were counted under the microscope. Loss of YB-1 decreased the average number difference of the colonies formed compared with the control. The size of the colonies was also significantly attenuated following loss of YB-1. C and D, SF188 control and shYB-1 cells were bilaterally injected into the hind flank of female nu/nu mice. Tumor incidence was monitored and 83% of the injection sites containing control SF188 cells developed tumors, whereas only 40% of those with shYB-1-containing cells developed lesions after 1 wk. By the second week, all of the mice developed tumors; however, there were significant differences in the tumor volume between the groups (those with shYB-1 were smallest) throughout the time course of 28 d. An example of these differences is illustrated where the control tumor was 26.21 mm³, whereas the shYB-1–expressing tumor was only 14.16 mm³. Differences in tumor size were determined using a Student’s t test (P < 0.05).

using a Euclidean distance measure with the complete linkage algorithm.7

Results and Discussion

Characterization of YB-1 in the Pediatric Glioblastoma Cell Line SF188

We characterized the SF188 pediatric glioblastoma cell line to show that it expresses high levels of YB-1 and pYB-15102, where it is primarily localized to the nucleus (Fig. 1A). It therefore served as a model to silence YB-1 stably and subsequently to study the ramifications(s) on tumor growth and sensitivity to chemotherapy. By stably expressing a shYB-1 plasmid, the level of YB-1 inhibition was confirmed to be reduced by >80% (Fig. 1B, left). Further, YB-1 was transiently silenced using siRNA and a 4-day time course was conducted. YB-1 was reduced by ~100% one day after transfection and this prominent knockdown was confirmed to be reduced by >80% (Fig. 1B, right). Thus, levels of YB-1 were manipulated by either stable or transient inhibition using siRNA for the studies that followed. We chose to use both short hairpin RNA (shRNA) and siRNA approaches with two different targeting sequences against YB-1 to validate our findings. In addition, concerns may arise with the shRNA approach given that after long-term culturing following the loss of YB-1 adaptive bypass mechanisms may develop, which could have introduced artifacts into the models.

Inhibition of YB-1 Suppresses the Tumorigenic Potential of SF188 Cell In vitro and In vivo

To understand how YB-1 may contribute to pediatric glioblastoma progression, YB-1 was silenced with either shRNA or siRNA and cellular invasion was examined 24 h later. Invasion was reduced by ~50% to 70% whether YB-1 was silenced stably or transiently compared with the control cells (Fig. 1C and D). Together, these results strongly suggest that attenuated YB-1 expression significantly inhibited SF188 cell invasiveness. These data are consistent with reports indicating that YB-1 regulates invasion proteases such as matrix metalloproteinase-2 (18). On further examination, the loss of YB-1 expression significantly inhibited tumor cell growth in monolayer after 8 days (Fig. 2A). Tumor cell growth was decreased by >70% when YB-1 was silenced compared with the cells treated with the scrambled control. Similarly, loss of YB-1 significantly reduced the number and size of colonies that formed in soft agar (Fig. 2B, top and bottom, respectively). In this model of pediatric glioblastoma, it appeared that YB-1 is needed for optimal tumor cell invasion and growth.

Collectively, these data supported the idea that inhibiting YB-1 may delay tumor growth in mice. Yet, the SF188 model had not been characterized in mice; therefore, a pilot study was conducted. SF188 control cells (1 × 106 per site) were injected into the lower right hind flank of female nu/nu mice (n = 12 animals). By the first week, 90% of the mice developed palpable tumors. By the end of the second week, all of the mice developed tumors. These data indicated that the SF188 cells were highly aggressive given the short amount of time needed for tumor development. At the end of this 30-day study, all of the mice developed tumors and spontaneous regression was never observed (Supplementary Fig. S1).

Once the tumors were collected at the termination of the study, we noted that they were fairly well vascularized and the average tumor size was 27 mm3 (Supplementary Fig. S1). Next, SF188 control and shYB-1 cells (1×106 per site) were bilaterally injected into the hind flank of female nu/nu mice. One week after injection, 83% of the mice developed tumors on the side where SF188 control cells were injected, indicating the reproducibility of tumor formation in this model compared with the wild-type SF188 cells described above. In contrast, only 40% of the mice had palpable tumors on another side where shYB-1 cells were injected (Fig. 2C). By the
second week, small tumors developed in this group; however, they grew much slower than the controls (Fig. 2D). The loss of YB-1 sustained growth suppression throughout the ensuing time course (Fig. 2D). Representative images of the tumors at the termination of the study illustrate differences in tumor size where the control was 26.1 mm$^3$ versus shYB-1–expressing tumor, which was only 14.16 mm$^3$ (Fig. 2D). Given the data presented here, where pediatric glioblastoma displays YB-1 dependency, we expect that it may also be a viable molecular target for brain tumors.

Inhibition of YB-1 Increased the Sensitivity of SF188 Cells to Temozolomide

Although we have shown that targeting YB-1 alone suppresses tumor growth in preclinical models, we realize that, in the clinical setting, inhibiting this target would likely involve combinations with current chemotherapies such as temozolomide. Initially, we characterized the SF188 cells for sensitivity to temozolomide and noted that it only inhibited growth in monolayer at relatively high doses (500 μmol/L; Supplementary Fig. S2A). Following this, SF188 cells were treated with 100, 500, or 1,000 μmol/L temozolomide for 24 h and apoptosis was assessed by flow cytometry using Annexin V. Overall, the cells were relatively insensitive to temozolomide, as it took 1,000 μmol/L to induce cell death and this was again quite marginal in that only 4% of the cell population underwent apoptosis (Supplementary Fig. S2B). Likewise, temozolomide failed to significantly inhibit SF188 growth in soft agar at doses up to 500 μmol/L (Supplementary Fig. S2C); therefore, we concluded that SF188 cells were not very sensitive to temozolomide. This is in keeping with a previous report indicating that the IC$_{50}$ of temozolomide was 426 ± 216 μmol/L for SF188 cells where cell growth was assessed in monolayer for 96 h (14). We therefore surmised that high levels of YB-1 might play a role in recalcitrance to temozolomide due to its role in mediating pleiotrophic resistance in other cancer models. We questioned whether silencing YB-1 would render cancer cells more sensitive to temozolomide by evaluating apoptosis through the induction of pH2AX$^{5139}$. Taxol was used as a positive control for the induction of apoptosis (15). We noted a dramatic increase in the pH2AX$^{5139}$ in SF188 shYB-1
cells compared with the control cells following exposure to temozolomide (Fig. 3A). As an aside, inhibiting YB-1 also sensitized the cells to Taxol (Fig. 3A), which confirms our recent report in a model of breast cancer (15). Similar findings were observed when the cells were treated with Taxol or temozolomide and apoptosis was measured by Annexin V or chromatin condensation (Supplementary Fig. S3A-C; Fig. 3B). Previous studies indicate that temozolomide insensitivity can be attributed to high levels of the DNA repair enzyme MGMT (19, 20). This led us to address whether inhibiting YB-1 causes SF188 cells to become more sensitive to temozolomide because it decreased MGMT levels. Yet, to our surprise, the mechanism of temozolomide sensitization was not related to MGMT because SF188 cells do not express this protein (Fig. 3C). Therefore, we surmise that the high expression of YB-1 is attributing to temozolomide resistance.

Given these intriguing findings, we next addressed whether YB-1 is highly expressed in primary adult glioblastoma. Previous studies indicated the YB-1 was among the top differentially expressed RNA regulatory factors in a comparison of 10 primary adult GBM multiforme and 10 nontumor control brain tissue samples (12). To expand these studies, we performed a similar analysis using data mined from Gene Expression Omnibus where 21 normal and 81 adult GBM were evaluated. Interestingly, in this larger data set, YB-1 expression remained among the top 25 differentially expressed genes (data not shown) and its expression was consistently higher in the tumors compared with normal tissues (Fig. 4A). Expression of YB-1 in normal samples strongly segregated from the tumors. It was noteworthy that only 8 high-grade GBM fell within the node containing the normal samples (Fig. 4A). This indicated that 90% (73 of 81 tumors) of the tumors had distinguishably higher levels of YB-1 compared with the control group. In further support of this finding, the adult glioblastoma cell lines U87 and U251 both express YB-1 as do the pediatric cell lines SJG2 and SF188 (Fig. 4B). In the U251 cell line, YB-1 and pYB-1S102 were readily detectable and mainly found in the nucleus (Fig. 4B). The presence of YB-1 was also readily detectable in the adult GBM cell line T98G (Fig. 4C). Therefore, its expression was silenced using siRNA resulting in a 90% decrease in protein and mRNA levels (Fig. 4C). The effect on cell growth was assessed over a time course of 3 days where loss of YB-1 markedly suppressed tumor cell proliferation (Fig. 4D).

To complement these studies, YB-1 was stably silenced in U251 cells using short hairpin RNA (Fig. 5A). This model was chosen given its relative insensitivity to temozolomide where the IC50 was about 600 μmol/L (21). The stable knockdown of YB-1 led to a ~90% reduction in its protein expression (Fig. 5A). Importantly, inhibiting YB-1 remarkably sensitized the U251 cells to temozolomide and Taxol (Fig. 5B). This was again independent of MGMT expression (Fig. 5C). Finally, we questioned whether YB-1 inhibition would have any effect in GBM cells that express MGMT. We inhibited YB-1 for 48 h and then exposed the cells to temozolomide for an additional 72 h. The loss of YB-1 further suppressed cell growth in the presence of temozolomide (Fig. 6A). This was not because YB-1 inhibited MGMT (Fig. 6B). This reinforces the idea that inhibiting YB-1 sensitizes brain tumor cells to temozolomide in a MGMT-independent manner.

At this time, we do not know how YB-1 is sensitizing GBM to apoptosis. One theory is that temozolomide induces DNA damage and that, when high levels of YB-1 are present, these defects may be repaired. There are indeed several examples in the literature attributing YB-1 to DNA repair (22–24). Thus, by inhibiting YB-1 in conjunction with temozolomide treatment, the DNA damage optimally triggers cell death (Fig. 6C). It is also possible that YB-1 may be regulating other methyltransferases.
that cleave adducts caused by temozolomide. This too awaits experimental verification. YB-1 has been associated previously with drug resistance; examples include cisplatin (26, 27), paclitaxel (28), and 5-flurouracil (29). Thus, it is quite conceivable that co-targeting YB-1 with classic anticancer agents could improve patient care. For example, YB-1–expressing tumors can be used to allow for replication of cytotoxic viruses that enhance the effect of chemotherapy (9). In fact, YB-1 is shown to be involved in the replication of adenovirus type 5, a commonly used vector in gene therapy. Therefore, it is suggested that YB-1 can trigger an oncolytic effect in YB-1 nuclear-positive cancer cells treated with adenoviruses (30). In closing, we conclude that inhibiting YB-1 has the potential to improve the treatment of GBM that arise in children and adults.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Dr. Kaiji Hu for the help in cell growth analysis.

References

Inhibition of YB-1 Slows Glioblastoma Multiforme Growth

Molecular Cancer Therapeutics

Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent $O^6$-methylguanine-DNA methyltransferase

Yuanyuan Gao, Abbas Fotovati, Cathy Lee, et al.

Mol Cancer Ther 2009;8:3276-3284. Published OnlineFirst December 8, 2009.

Updated version
Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-09-0478

Supplementary Material
Access the most recent supplemental material at: http://mct.aacrjournals.org/content/suppl/2009/12/14/1535-7163.MCT-09-0478.DC1

Cited articles
This article cites 30 articles, 14 of which you can access for free at: http://mct.aacrjournals.org/content/8/12/3276.full.html#ref-list-1

Citing articles
This article has been cited by 8 HighWire-hosted articles. Access the articles at: /content/8/12/3276.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.